Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2180 publications

Bullous pemphigoid associated with canagliflozin intake.

Bullous pemphigoid associated with canagliflozin intake.

Journal: Italian journal of dermatology and venereology
Published: October 03, 2025

Simultaneous estimation of finerenone and canagliflozin using HPLC: application in metabolic stability studies.

Simultaneous estimation of finerenone and canagliflozin using HPLC: application in metabolic stability studies.

Journal: Bioanalysis
Published: September 29, 2025

Canagliflozin inhibits electrogenic Na+ transport in mouse cortical collecting duct cells.

Canagliflozin inhibits electrogenic Na+ transport in mouse cortical collecting duct cells.

Journal: Function (Oxford, England)
Published: August 19, 2025

Canagliflozin ameliorates high-salt-induced renal injury and premature aging in male Dahl salt-sensitive rats, with associated changes in SIRT6/HIF-1α signaling.

Canagliflozin ameliorates high-salt-induced renal injury and premature aging in male Dahl salt-sensitive rats, with associated changes in SIRT6/HIF-1α signaling.

Journal: Renal failure
Published: August 12, 2025

SGLT-2 inhibitors beyond diabetes: A new frontier in cancer treatment.

SGLT-2 inhibitors beyond diabetes: A new frontier in cancer treatment.

Journal: Diabetes research and clinical practice
Published: August 11, 2025

Association Between Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use and All-Cause Mortality in Patients With Pulmonary Arterial Hypertension.

Association Between Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use and All-Cause Mortality in Patients With Pulmonary Arterial Hypertension.

Journal: Cureus
Published: August 05, 2025

Long-Term Cardiorenal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Real-World Single-Center Experience.

Long-Term Cardiorenal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Real-World Single-Center Experience.

Journal: Journal of clinical medicine
Published: August 05, 2025

Summary for Patients: Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes.

Summary for Patients: Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes.

Journal: Annals of internal medicine
Published: August 04, 2025

Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.

Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.

Journal: Annals of internal medicine
Published: August 04, 2025

Expanding the Treatment Vault: Canagliflozin in Youth With Type 2 Diabetes.

Expanding the Treatment Vault: Canagliflozin in Youth With Type 2 Diabetes.

Journal: Annals of internal medicine
Published: August 04, 2025

Managing the side effects of sodium-glucose cotransporter-2 inhibitors.

Managing the side effects of sodium-glucose cotransporter-2 inhibitors.

Journal: Cleveland Clinic journal of medicine
Published: August 01, 2025

SGLT2 inhibitors and acute kidney injury.

SGLT2 inhibitors and acute kidney injury.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: July 30, 2025
Showing 1-12 of 2,180

Last Updated: 10/31/2025